These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15148985)

  • 1. Industrial interests versus public health: the gap is growing.
    Prescrire Int; 2004 Apr; 13(70):71-6. PubMed ID: 15148985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A generic problem.
    Hanauer SB
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
    [No Abstract]   [Full Text] [Related]  

  • 3. Generic medicine pricing in Europe: current issues and future perspective.
    Simoens S
    J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification.
    Smart A; Martin P
    Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):583-601. PubMed ID: 16980196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug marketing exclusivity under United States and European Union law.
    Junod V
    Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
    [No Abstract]   [Full Text] [Related]  

  • 7. Packaging of pharmaceuticals: still too many dangers but several encouraging initiatives.
    Prescrire Int; 2007 Jun; 16(89):126-8. PubMed ID: 17585428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Future challenges and prospects for drug companies].
    Lajoux C
    Bull Acad Natl Med; 2008 Apr; 192(4):623-30; discussion 630-2. PubMed ID: 19024935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Big pharma and health care: unsolvable conflict of interests between private enterprise and public health.
    Brezis M
    Isr J Psychiatry Relat Sci; 2008; 45(2):83-9; discussion 90-4. PubMed ID: 18982834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New drugs and indications in 2011. France is better focused on patients' interests after the Mediator scandal, but stagnation elsewhere.
    Prescrire Int; 2012 Apr; 21(126):106-10. PubMed ID: 22515141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Better medicines for children].
    Brasseur D
    Rev Med Brux; 2006; 27 Spec No():Sp25-8. PubMed ID: 21818889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Draft EU regulation on paediatric medicines: some improvements but still far from perfect.
    Prescrire Int; 2006 Feb; 15(81):32-3. PubMed ID: 16548115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fake drugs, what are we talking about? Counterfeit drugs, informal market, quality of pharmaceutical… Thought from an anthropological study led in Benin].
    Baxerres C
    Bull Soc Pathol Exot; 2014 May; 107(2):121-6. PubMed ID: 24639135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of new drugs and indications in 2002: financial speculation or better patent care?
    Prescrire Int; 2003 Apr; 12(64):74-7. PubMed ID: 12674131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Provision of information on regulatory authorities' websites.
    Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
    Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Public health benefits of non prescription medicines and self care].
    Baumelou A
    Bull Acad Natl Med; 2007 Nov; 191(8):1527-31. PubMed ID: 18666454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Charter of medicines promotion and rational use by physicians].
    Baumevieille M; Bégaud B; Maurain C
    Therapie; 2007; 62(1):39-44. PubMed ID: 17374346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.